REGENXBIO Faces Securities Investigation After FDA Clinical Holds

REGENXBIO is under investigation by Levi & Korsinsky for potential violations of federal securities laws. This follows the United States===Food and Drug Administration's decision to place clinical holds on REGENXBIO's RGX-111 and RGX-121 programs due to the identification of a tumor in a trial participant. The disclosure of these clinical holds on January 28, 2026, caused REGENXBIO's share price to decline by 30-35%. The investigation focuses on whether REGENXBIO, particularly its CEO Curran Simpson, failed to provide complete and accurate material information to investors, especially during the Q3 2025 earnings call where positive regulatory interactions were emphasized without mentioning ongoing safety concerns.